Literature DB >> 31419753

Clinical and genetic analysis of melanomas arising in acral sites.

Anne Zaremba1, Rajmohan Murali2, Philipp Jansen1, Inga Möller1, Antje Sucker1, Annette Paschen1, Lisa Zimmer1, Elisabeth Livingstone1, Titus J Brinker3, Eva Hadaschik1, Cindy Franklin4, Alexander Roesch1, Selma Ugurel1, Dirk Schadendorf1, Klaus G Griewank5, Ioana Cosgarea6.   

Abstract

STUDY AIM: Melanomas arising in acral sites are associated with a poorer prognosis than other melanoma subtypes. The aim of this study was to evaluate clinical-pathological and genetic characteristics as well as therapeutic responses of a larger cohort of patients with melanomas arising in acral sites.
METHODS: Clinical data of 134 patients with melanomas arising in acral sites from the Dept. of Dermatology Essen were collected and analysed with regard to clinicopathological characteristics and treatment responses. Genetic analysis with targeted next-generation sequencing was done on 50 samples.
RESULTS: In our cohort, BRAF (30%), NRAS (28%), TERT promoter (26%), NF1 (14%) and KIT (6%) were frequently identified mutations. Comparing tumours situated on palms and soles with melanomas arising on dorsal acral sites, a higher frequency of NRAS (39.1% versus 25%) and NF1 (17.3% versus 0%) and lower frequencies of BRAF (21.7% versus 75%) and TERT promoter (8.6% versus 50%) mutations were observed. MAPK activating mutations were identified in 64% of tumours. Overall survival was longer in patients treated with immune checkpoint inhibitors as first-line treatment than in patients receiving other systemic therapies (i.e. BRAF/MEK inhibitors and chemotherapy).
CONCLUSION: Our data suggest that the genetics of melanomas arising in acral sites varies by tumour location and may influence biological behaviour.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acral melanoma; Immune checkpoint inhibitor treatment; Melanoma treatment; Melanomas arising in acral sites; Next-generation sequencing; TERT promotor mutation

Mesh:

Substances:

Year:  2019        PMID: 31419753      PMCID: PMC8140290          DOI: 10.1016/j.ejca.2019.07.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  Melanoma subtypes demonstrate distinct PD-L1 expression profiles.

Authors:  Genevieve J Kaunitz; Tricia R Cottrell; Mohammed Lilo; Valliammai Muthappan; Jessica Esandrio; Sneha Berry; Haiying Xu; Aleksandra Ogurtsova; Robert A Anders; Alexander H Fischer; Stefan Kraft; Meg R Gerstenblith; Cheryl L Thompson; Kord Honda; Jonathan D Cuda; Charles G Eberhart; James T Handa; Evan J Lipson; Janis M Taube
Journal:  Lab Invest       Date:  2017-07-24       Impact factor: 5.662

2.  Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients.

Authors:  Y Teramoto; U Keim; A Gesierich; G Schuler; E Fiedler; T Tüting; C Ulrich; U Wollina; J C Hassel; R Gutzmer; S Goerdt; C Zouboulis; U Leiter; T K Eigentler; C Garbe
Journal:  Br J Dermatol       Date:  2017-12-20       Impact factor: 9.302

3.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

4.  Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.

Authors:  Alexandra M Haugh; Bin Zhang; Victor L Quan; Erin M Garfield; Jeffrey A Bubley; Emily Kudalkar; Anna Elisa Verzi; Kara Walton; Timothy VandenBoom; Emily A Merkel; Christina Y Lee; Timothy Tan; Maria Cristina Isales; Betty Y Kong; Alexander T Wenzel; Christopher G Bunick; Jaehyuk Choi; Jeffrey Sosman; Pedram Gerami
Journal:  J Invest Dermatol       Date:  2017-09-01       Impact factor: 8.551

5.  Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.

Authors:  Cristina Carrera; Adrià Gual; Alba Díaz; Joan A Puig-Butillé; Susanna Noguès; Antonio Vilalta; Carlos Conill; Ramón Rull; Ramon Vilana; Pedro Arguis; Sergi Vidal-Sicart; Llucia Alós; Josep Palou; Teresa Castel; Josep Malvehy; Susana Puig
Journal:  Melanoma Res       Date:  2017-08       Impact factor: 3.599

6.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

7.  Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Authors:  Adil I Daud; Jedd D Wolchok; Caroline Robert; Wen-Jen Hwu; Jeffrey S Weber; Antoni Ribas; F Stephen Hodi; Anthony M Joshua; Richard Kefford; Peter Hersey; Richard Joseph; Tara C Gangadhar; Roxana Dronca; Amita Patnaik; Hassane Zarour; Charlotte Roach; Grant Toland; Jared K Lunceford; Xiaoyun Nicole Li; Kenneth Emancipator; Marisa Dolled-Filhart; S Peter Kang; Scot Ebbinghaus; Omid Hamid
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

8.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

9.  PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Authors:  Jason Madore; Ricardo E Vilain; Alexander M Menzies; Hojabr Kakavand; James S Wilmott; Jessica Hyman; Jennifer H Yearley; Richard F Kefford; John F Thompson; Georgina V Long; Peter Hersey; Richard A Scolyer
Journal:  Pigment Cell Melanoma Res       Date:  2014-12-22       Impact factor: 4.693

10.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Antje Sucker; Daniel J Treacy; Cory M Johannessen; Eva M Goetz; Chelsea S Place; Amaro Taylor-Weiner; Steven Whittaker; Gregory V Kryukov; Eran Hodis; Mara Rosenberg; Aaron McKenna; Kristian Cibulskis; Deborah Farlow; Lisa Zimmer; Uwe Hillen; Ralf Gutzmer; Simone M Goldinger; Selma Ugurel; Helen J Gogas; Friederike Egberts; Carola Berking; Uwe Trefzer; Carmen Loquai; Benjamin Weide; Jessica C Hassel; Stacey B Gabriel; Scott L Carter; Gad Getz; Levi A Garraway; Dirk Schadendorf
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

View more
  15 in total

Review 1.  Emerging strategies to treat rare and intractable subtypes of melanoma.

Authors:  Gretchen M Alicea; Vito W Rebecca
Journal:  Pigment Cell Melanoma Res       Date:  2020-04-24       Impact factor: 4.693

2.  NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.

Authors:  Carl M Thielmann; Eleftheria Chorti; Johanna Matull; Rajmohan Murali; Anne Zaremba; Georg Lodde; Philipp Jansen; Luisa Richter; Julia Kretz; Inga Möller; Antje Sucker; Rudolf Herbst; Patrick Terheyden; Jochen Utikal; Claudia Pföhler; Jens Ulrich; Alexander Kreuter; Peter Mohr; Ralf Gutzmer; Friedegund Meier; Edgar Dippel; Michael Weichenthal; Annette Paschen; Elisabeth Livingstone; Lisa Zimmer; Dirk Schadendorf; Eva Hadaschik; Selma Ugurel; Klaus G Griewank
Journal:  Eur J Cancer       Date:  2021-11-04       Impact factor: 10.002

3.  Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival.

Authors:  Carl Maximilian Thielmann; Johanna Matull; Sebastian Roth; Jan-Malte Placke; Eleftheria Chorti; Anne Zaremba; Georg Lodde; Philipp Jansen; Frederik Krefting; Julia Kretz; Inga Möller; Antje Sucker; Annette Paschen; Elisabeth Livingstone; Lisa Zimmer; Selma Ugurel; Dirk Schadendorf; Eva Hadaschik; Klaus G Griewank
Journal:  Cancers (Basel)       Date:  2022-04-22       Impact factor: 6.575

4.  Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review.

Authors:  Qingyue Zheng; Jiarui Li; Hanlin Zhang; Yuanzhuo Wang; Shu Zhang
Journal:  Front Oncol       Date:  2020-12-03       Impact factor: 6.244

5.  The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma.

Authors:  Xiaoting Wei; Di Wu; Hang Li; Rui Zhang; Yu Chen; Hong Yao; Zhihong Chi; Xinan Sheng; Chuanliang Cui; Xue Bai; Zhonghui Qi; Ke Li; Shijie Lan; Lizhu Chen; Rui Guo; Xinyu Yao; Lili Mao; Bin Lian; Yan Kong; Jie Dai; Bixia Tang; Xieqiao Yan; Xuan Wang; Siming Li; Li Zhou; Charles M Balch; Lu Si; Jun Guo
Journal:  Ann Surg Oncol       Date:  2020-04-06       Impact factor: 5.344

Review 6.  Cutaneous and Mucosal Melanomas of Uncommon Sites: Where Do We Stand Now?

Authors:  Emi Dika; Martina Lambertini; Cristina Pellegrini; Giulia Veronesi; Barbara Melotti; Mattia Riefolo; Francesca Sperandi; Annalisa Patrizi; Costantino Ricci; Martina Mussi; Maria Concetta Fargnoli
Journal:  J Clin Med       Date:  2021-01-28       Impact factor: 4.241

7.  The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI).

Authors:  Lisa Elefanti; Carolina Zamuner; Paolo Del Fiore; Camilla Stagni; Stefania Pellegrini; Luigi Dall'Olmo; Alessio Fabozzi; Rebecca Senetta; Simone Ribero; Roberto Salmaso; Simone Mocellin; Franco Bassetto; Francesco Cavallin; Anna Lisa Tosi; Francesca Galuppini; Angelo Paolo Dei Tos; Chiara Menin; Rocco Cappellesso
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

8.  Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis.

Authors:  Farshad Farshidfar; Kahn Rhrissorrakrai; Chaya Levovitz; Cong Peng; James Knight; Antonella Bacchiocchi; Juan Su; Mingzhu Yin; Mario Sznol; Stephan Ariyan; James Clune; Kelly Olino; Laxmi Parida; Joerg Nikolaus; Meiling Zhang; Shuang Zhao; Yan Wang; Gang Huang; Miaojian Wan; Xianan Li; Jian Cao; Qin Yan; Xiang Chen; Aaron M Newman; Ruth Halaban
Journal:  Nat Commun       Date:  2022-02-23       Impact factor: 17.694

Review 9.  More than just acral melanoma: the controversies of defining the disease.

Authors:  Sara S Bernardes; Ingrid Ferreira; David E Elder; Aretha B Nobre; Héctor Martínez-Said; David J Adams; Carla Daniela Robles-Espinoza; Patricia A Possik
Journal:  J Pathol Clin Res       Date:  2021-07-02

10.  Characterizations of Gene Alterations in Melanoma Patients from Chinese Population.

Authors:  Yi Luo; Zhenzhen Zhang; Jianfan Liu; Linqing Li; Xuezheng Xu; Xinyu Yao; Zixun Dai; Xin Wang; Shuo Yang; Hongwei Wu; Jie Bu; Yuan Wu; Tianmin Xiang; Xianan Li
Journal:  Biomed Res Int       Date:  2020-01-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.